These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 31457033)

  • 1. Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers.
    Falahatgar D; Farajnia S; Zarghami N; Tanomand A; Khosroshahi SA; Akbari B; Farajnia H
    Iran J Biotechnol; 2018 Dec; 16(4):e1743. PubMed ID: 31457033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
    Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
    Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
    Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
    Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.
    Sokolova EA; Stremovskiy OA; Zdobnova TA; Balalaeva IV; Deyev SM
    Acta Naturae; 2015; 7(4):93-6. PubMed ID: 26798495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
    Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
    Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
    Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
    Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The construction of anti-EGFR single chain variable fragment fused with gelonin toxin prokaryotic expressing plasmid and the study of its anti-tumor effects].
    Qiu J; Li Q; Li XL; Zhou XK; Huang NY; Li J
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 42(5):621-4. PubMed ID: 22007484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic Chaperones Enhance Soluble Expression of Anti-EGFR huscFv in
    Nazari A; Farajnia S; Zahri S; Bagherlou N; Tanoumand A; Rahbarnia L
    Iran J Biotechnol; 2020 Apr; 18(2):e2314. PubMed ID: 33542937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
    Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
    Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
    Sarnovsky R; Tendler T; Makowski M; Kiley M; Antignani A; Traini R; Zhang J; Hassan R; FitzGerald DJ
    Cancer Immunol Immunother; 2010 May; 59(5):737-46. PubMed ID: 20091030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity.
    Jun SY; Kim DS; Kim YS
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cytotoxicity of a
    Masilamani AP; Huber N; Nagl C; Dettmer-Monaco V; Monaco G; Wolf I; Schultze-Seemann S; Taromi S; Gratzke C; Fuchs H; Wolf P
    Front Pharmacol; 2023; 14():1211824. PubMed ID: 37484018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
    Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
    Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a recombinant hCG-specific single chain immunotoxin cytotoxic to hCG expressing cancer cells.
    Nand KN; Gupta JC; Panda AK; Jain SK
    Protein Expr Purif; 2015 Feb; 106():10-7. PubMed ID: 25448825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells
    Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
    Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research.
    Damough S; Bayat E; Oghabi Bakhshaiesh T; Barkhordari F; Esmaeili R; Nematollahi L; Talebkhan Y
    Ann Med Surg (Lond); 2023 Sep; 85(9):4348-4354. PubMed ID: 37663730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.
    Simon N; FitzGerald D
    Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR).
    Ahdi Khosroshahi S; Farajnia S; Ghiamirad M; Tanomand A; Veisi K; Rahbarnia L; Akbari B
    Protein Expr Purif; 2016 Apr; 120():59-64. PubMed ID: 26690373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.